NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
MobiKwik FY26 Results: Subsidiary Revenue Reaches ₹188.3 Cr with Net Loss of ₹7.98 Cr
One Mobikwik Systems Limited has approved its audited financial results for the quarter and year ended March 31, 2026. The consolidated performance of its six subsidiaries shows a total revenue of Rs. 1,882.66 million (approx. ₹188.3 crore) for the full financial year. However, these subsidiaries collectively reported a net loss of Rs. 79.81 million (approx. ₹7.98 crore). The auditors have issued an unmodified opinion, indicating that the financial statements provide a true and fair view of the company's financial health.
முக்கிய அம்சங்கள்
Total revenue from six key subsidiaries stood at Rs. 1,882.66 million for the financial year ended March 31, 2026.Subsidiaries reported a combined net loss after tax of Rs. 79.81 million for the same period.Total assets for the subsidiary group were recorded at Rs. 1,520.30 million as of year-end.The group maintained positive net cash inflows of Rs. 23.03 million for the year.Auditors B S R and Co provided an unmodified audit report for the consolidated annual financial results.
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the company's progress toward consolidated profitability as it scales its lending and payment subsidiaries. The focus should remain on the narrowing of losses and the growth trajectory of the high-margin financial services segments.
Biocon Pharma Receives Health Canada Approval for Micafungin 50mg and 100mg
Biocon Pharma Limited, a subsidiary of Biocon Limited, has secured regulatory approval from Health Canada for Micafungin for Injection, USP, in 50 mg and 100 mg strengths. This antifungal medication is indicated for treating serious infections like Candidemia and esophageal candidiasis in adults and children aged four months and older. It is also approved for prophylaxis in patients undergoing hematopoietic stem cell transplantation. This approval marks a significant step in expanding Biocon's generic portfolio within the regulated North American market.
முக்கிய அம்சங்கள்
Health Canada approval granted for Micafungin for Injection in 50 mg and 100 mg dosages.Indicated for treatment of Candidemia, Acute Disseminated Candidiasis, and Candida Peritonitis.Approved for use in pediatric patients as young as four months and adults.Strengthens Biocon's integrated biosimilars and generics portfolio in the Canadian market.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that enhances Biocon's revenue potential in the generics segment. Monitor the company's execution and market share capture in the Canadian antifungal market.
Birla Corp FY26 Net Profit Surges 89% to ₹558 Cr; Record Cement Sales of 18.72 MT
Birla Corporation reported a robust FY26 performance with net profit nearly doubling to ₹558 crore, driven by record cement sales volumes and improved operational efficiencies. The company achieved a high capacity utilization of 95%, significantly outperforming the industry average of 70%. While Q4 revenue remained flat at ₹2,875 crore due to subdued realizations, the full-year EBITDA per ton improved by 15.1% to ₹786. The company successfully expanded its annual capacity to 21.4 mt following the commissioning of the Kundanganj Line III in March.
முக்கிய அம்சங்கள்
Full-year net profit jumped 89% YoY to ₹558 crore, with Q4 profit rising 15% to ₹295 crore.Cement sales reached a record high of 18.72 million tons with a 95% capacity utilization rate.Annual production capacity increased to 21.4 mt from 20 mt after commissioning Kundanganj Line III.Premium cement sales grew 18% YoY, accounting for 61% of total trade channel sales.Full-year EBITDA margin expanded by over 200 basis points to 16.2% despite pricing headwinds.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's superior capacity utilization and successful premiumization strategy which is protecting margins despite industry-wide pricing pressure. The stock remains a strong play on the infrastructure sector given its recent capacity expansion and operational efficiency gains.
Birla Corp Recommends ₹12.50 Dividend; Extends CS Manoj Mehta's Term for 4 Years
Birla Corporation has recommended a dividend of ₹12.50 per share (125%) for the financial year 2025-26, pending shareholder approval. The Board also approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. To ensure governance continuity, the company extended the term of Shri Manoj Kumar Mehta, Company Secretary and Legal Head, for a further four years until October 2030. Mr. Mehta has been with the company since 2006 and possesses 35 years of experience in legal and corporate affairs.
முக்கிய அம்சங்கள்
Recommended a dividend of ₹12.50 per share (125%) on 7,70,05,347 ordinary shares for FY 2025-26.Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.Extended the term of Shri Manoj Kumar Mehta as CS & Legal Head for 4 years effective November 1, 2026.Shri Mehta is a CA and CS with 35 years of experience and has been with Birla Corp for 20 years.
👀 கவனிக்க வேண்டியவை
Investors should benefit from the ₹12.50 dividend payout and the stability in key managerial personnel. It is advised to review the full financial results to assess the company's operational efficiency and margin performance in the cement sector.
Biocon Proposes CEO Appointment and Revision in Executive Chairperson's Remuneration
Biocon Limited has initiated a postal ballot to seek shareholder approval for several key leadership and structural changes. The company proposes appointing Mr. Shreehas Pradeep Tambe as CEO & MD for a five-year term starting April 1, 2026. Additionally, it seeks to revise Executive Chairperson Kiran Mazumdar-Shaw's annual remuneration to a cap of ₹21 crore from Biocon and ₹25 crore on a consolidated basis with Syngene. The ballot also includes a proposal for a preferential issue of equity shares for consideration other than cash, indicating potential inorganic growth or asset acquisition.
முக்கிய அம்சங்கள்
Appointment of Shreehas Pradeep Tambe as CEO & MD for a 5-year term effective April 1, 2026Revision of Kiran Mazumdar-Shaw's remuneration cap to ₹21 crore per annum from BioconConsolidated remuneration cap for Ms. Shaw (including Syngene) set at ₹25 crore per annumProposal for issuance of equity shares on a preferential basis for consideration other than cashAppointment or re-appointment of 7 Independent and Non-Executive Directors to the Board
👀 கவனிக்க வேண்டியவை
Investors should monitor the specific details regarding the preferential issue for non-cash consideration as it may signal a strategic acquisition. The leadership transition to Mr. Tambe is a significant long-term development for the company's execution strategy.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
SBIN Declares ₹17.35 Dividend per Share; Sets May 16 as Record Date
State Bank of India (SBIN) has declared a dividend of ₹17.35 per equity share for the financial year ended March 31, 2026. This represents a significant payout of 1735% on the face value of ₹1 per share. The bank has fixed May 16, 2026, as the record date to determine shareholder eligibility for this payout. The dividend is scheduled to be paid to eligible shareholders on June 4, 2026.
முக்கிய அம்சங்கள்
Dividend declared at ₹17.35 per equity share of face value ₹1 (1735%)Record date for determining eligibility is fixed as May 16, 2026Dividend payment date is scheduled for June 4, 2026Book closure period set from May 17, 2026, to May 19, 2026Announcement follows the Central Board meeting held on May 8, 2026
👀 கவனிக்க வேண்டியவை
Investors seeking to receive the dividend must ensure they hold SBIN shares in their demat account before the ex-dividend date. The ₹17.35 payout offers a healthy yield for long-term shareholders of India's largest public sector bank.
SBI Reports Record Annual Net Profit of ₹80,032 Cr in FY26; GNPA at Two-Decadal Low of 1.49%
State Bank of India (SBI) delivered its highest-ever annual net profit of ₹80,032 crores for FY26, marking a 12.88% YoY growth. The bank's loan book expanded robustly by 16.87% to ₹49.3 lakh crore, driven by strong growth in SME (21%) and Agri (19.7%) segments. Asset quality reached a multi-decade high with GNPA and NNPA ratios improving to 1.49% and 0.39% respectively. While Net Interest Margins (NIM) saw a slight compression of 17-18 bps, the bank maintained a healthy ROE of 18.57% and strengthened its capital adequacy to 15.40%.
முக்கிய அம்சங்கள்
Highest ever annual Net Profit of ₹80,032 crores, growing 12.88% YoY with ROE at 18.57%.Gross NPA ratio hit a two-decadal low of 1.49% and Net NPA at 0.39% with credit cost at 0.37%.Total advances grew 16.87% YoY to ₹49.3 lakh crore, while deposits rose 11.03% to ₹59.8 lakh crore.Capital Adequacy Ratio (CAR) improved by 115 bps YoY to reach 15.40%.Digital leadership continues with YONO registered users crossing 10.02 crore and 66% of savings accounts opened digitally.
👀 கவனிக்க வேண்டியவை
Investors should maintain a positive outlook as SBI demonstrates best-in-class asset quality and robust credit growth across all segments. The minor NIM compression is offset by operating efficiencies and lower credit costs, making it a preferred pick in the banking sector.
Biocon Q4 FY26: Adjusted EBITDA up 29% YoY to ₹1,073 Cr; Biosimilars Drive Growth
Biocon reported a steady Q4 FY26 with consolidated revenue from operations reaching ₹4,517 crore, representing a 10% adjusted YoY growth. The Biosimilars segment remains the primary growth engine, contributing ₹2,756 crore in Q4 with a healthy 26% EBITDA margin. The company has successfully completed the integration of Biocon Biologics and is transitioning from a heavy investment phase to an execution phase focused on margin expansion and deleveraging. While the Generics segment saw a margin improvement to 8%, the CRDMO (Syngene) segment showed modest growth of 2% YoY.
முக்கிய அம்சங்கள்
Q4 FY26 consolidated revenue grew 10% YoY (adjusted for one-time sales) to ₹4,517 crore.Adjusted EBITDA for Q4 rose 29% YoY to ₹1,073 crore, with margins improving to 23%.Biosimilars segment revenue grew 12% YoY to ₹2,756 crore, supported by strong performance in North America.Generics segment EBITDA margin improved 300 bps QoQ to 8%, driven by gLiraglutide launches in Europe.Full-year FY26 revenue reached ₹16,927 crore with a 25% adjusted growth in EBITDA.
👀 கவனிக்க வேண்டியவை
Investors should monitor the ramp-up of recent biosimilar launches and the utilization of new generic facilities to confirm margin expansion. The completion of the Biocon Biologics integration and the shift toward deleveraging makes the company a strong long-term play on global biosimilars.
Biocon Declares Re 0.50 Dividend; To Acquire Remaining 2% Stake in Biocon Biologics for Rs 330 Cr
Biocon's board has recommended a final dividend of Re. 0.50 per share (10%) for FY26, setting July 03, 2026, as the record date. A major strategic move involves acquiring the remaining ~2% stake in its subsidiary, Biocon Biologics, through a preferential issue of 87.92 lakh shares at Rs 376.16 per share, totaling approximately Rs 330.73 crore. The company is also undergoing a significant board and management overhaul to integrate Biocon and Biocon Biologics into a unified global entity. Additionally, S.R. Batliboi & Associates has been appointed as the new statutory auditor for a five-year term.
முக்கிய அம்சங்கள்
Recommended final dividend of Re. 0.50 per equity share (10% of face value) for FY26.Fixed July 03, 2026, as the record date for dividend entitlement with payment by August 31, 2026.Approved acquisition of ~2% stake in Biocon Biologics via preferential issue of 87,92,317 shares at Rs 376.16 per share.Total consideration for the Biocon Biologics stake acquisition is approximately Rs 330.73 crore.Major board restructuring with the appointment of five new Independent Directors to facilitate subsidiary integration.
👀 கவனிக்க வேண்டியவை
Investors should track the July 03 record date for dividend eligibility and view the consolidation of Biocon Biologics as a positive step toward a simplified corporate structure. The preferential issue price of Rs 376.16 serves as a key valuation benchmark for the parent company.
Biocon Q4FY26: Adj. Net Profit Jumps 64% to Rs 179 Cr; EBITDA Up 29% to Rs 1,073 Cr
Biocon reported a strong performance for Q4FY26 with adjusted operating revenue growing 10% YoY to Rs 4,517 crore. The company achieved significant margin expansion, with adjusted EBITDA rising 29% to Rs 1,073 crore and adjusted Net Profit increasing 64% to Rs 179 crore. The Biosimilars segment remains the core growth driver, contributing Rs 2,756 crore in Q4 revenue. For the full year FY26, adjusted Net Profit surged 323% to Rs 436 crore, and the board recommended a final dividend of Rs 0.50 per share.
முக்கிய அம்சங்கள்
Q4FY26 adjusted Net Profit grew 64% YoY to Rs 179 crore; FY26 adjusted Net Profit rose 323% to Rs 436 crore.Consolidated EBITDA margin for FY26 expanded by 200 basis points to 22% on a like-to-like basis.Biosimilars segment revenue grew 12% YoY in Q4 to Rs 2,756 crore with a healthy 26% EBITDA margin.Generics segment showed recovery with 13% adjusted revenue growth in Q4 and a 300 bps sequential margin improvement to 8%.Board recommended a final dividend of Rs 0.50 per share (10% of face value) for FY26.
👀 கவனிக்க வேண்டியவை
Investors should view the margin expansion and successful integration of the biosimilars business as a positive sign of operational efficiency. Monitor the scale-up of recent US launches like Denosumab and the performance of the CRDMO (Syngene) segment for long-term value creation.
Bigbloc Construction Commences Commercial Production at Umargaon Chemicals Plant
Bigbloc Construction's wholly owned subsidiary, Bigbloc Building Elements Private Limited, has officially started commercial production at its Umargaon facility as of May 7, 2026. This follows the successful completion of trial production which began on April 17, 2026. The new plant focuses on manufacturing construction chemicals, representing a strategic expansion into high-value construction materials. This milestone is expected to enhance the company's product portfolio and drive future revenue growth through diversification.
முக்கிய அம்சங்கள்
Commercial production at Umargaon facility commenced on May 7, 2026Facility is operated by 100% subsidiary Bigbloc Building Elements Private LimitedStrategic entry into the high-growth construction chemicals segmentSuccessful transition from trial production which started on April 17, 2026
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive growth catalyst and monitor the facility's capacity utilization and its impact on margins in upcoming quarterly reports.
Biocon Denies Succession Rumors; Kiran Mazumdar-Shaw to Continue as Executive Chairperson
Biocon Limited has officially clarified to the stock exchanges that media reports regarding the appointment of Claire Mazumdar as successor are incorrect. The company stated that Kiran Mazumdar-Shaw continues to serve as the Executive Chairperson and is not stepping down from her role. The management emphasized that the company is currently led by a professional team under CEO & Managing Director Shreehas Tambe. This clarification was issued on May 6, 2026, following a query from BSE and NSE regarding speculative news and material price movement.
முக்கிய அம்சங்கள்
Biocon denies reports of Claire Mazumdar being chosen as successor to Kiran Mazumdar-Shaw.Kiran Mazumdar-Shaw remains the Executive Chairperson with no impending change in management.Company confirms no material information regarding ownership succession exists under SEBI Regulation 30.Professional leadership continues under CEO & Managing Director Shreehas Tambe.Clarification follows stock exchange queries regarding price movement on May 6, 2026.
👀 கவனிக்க வேண்டியவை
Investors should disregard speculative media reports and focus on the company's operational performance under the existing professional leadership. The clarification removes immediate uncertainty regarding a leadership transition.
BIL Vyapar Cites CIRP for Non-Applicability of Corporate Governance Reporting for Q4 FY26
BIL Vyapar Limited (formerly Binani Industries Limited) has informed stock exchanges that Regulation 27 regarding Corporate Governance reporting is not applicable for the quarter and year ended March 31, 2026. The company is currently undergoing the Corporate Insolvency Resolution Process (CIRP), which commenced on January 13, 2026. Ms. Rachana Jhunjhunwala has been appointed as the Resolution Professional to oversee the company's affairs. Under SEBI Regulation 15, companies under CIRP are exempt from specific governance compliance filings.
முக்கிய அம்சங்கள்
Company entered Corporate Insolvency Resolution Process (CIRP) effective January 13, 2026.Ms. Rachana Jhunjhunwala appointed as the Resolution Professional for the insolvency proceedings.Exemption from Regulation 27 (Corporate Governance) claimed for the fourth quarter and full year ended March 31, 2026.The filing follows SEBI (LODR) Regulation 15 which provides relief to companies under insolvency.
👀 கவனிக்க வேண்டியவை
Investors should exercise extreme caution as the company is in insolvency proceedings, which often results in significant equity dilution or delisting. Monitor the progress of the resolution plan for any updates on potential recovery value for shareholders.
Tasty Bite Shareholders Reject Material Related Party Transactions with Mars Food UK
Tasty Bite Eatables shareholders have rejected two critical resolutions regarding material related party transactions (RPT) with Mars Food UK and Preferred Brands International for FY 2025-26 and FY 2026-27. Over 98% of the voting public shareholders, including institutions, opposed these RPT resolutions, leading to their failure. While the RPTs were blocked, shareholders did approve revised remuneration packages for the Managing Director, Whole Time Director, and Chairman. This significant dissent on RPTs could pose operational challenges given the company's integrated business model with its global parent.
முக்கிய அம்சங்கள்
Resolution 1 for RPTs in FY 2026-27 failed with 98.68% of polled votes cast against the proposal.Resolution 5 for continuing transactions with Mars Food UK for FY 2025-26 failed with 98.71% votes against.Public institutional investors voted overwhelmingly against RPTs, with 91,841 votes against versus only 1,291 in favor.Remuneration revisions for MD Dilen Gandhi and WTD Shashank Shekhar passed with over 95% total favor votes.The postal ballot saw participation from 19,682 shareholders as of the March 27, 2026 record date.
👀 கவனிக்க வேண்டியவை
Investors should exercise caution as the rejection of material related party transactions may disrupt the company's supply chain and sales to group entities. Monitor for management's response or revised proposals to address shareholder concerns regarding transaction terms.
SBI Shortlists 8 Candidates for Election of 4 Directors to Central Board
State Bank of India (SBI) has released the list of eight validly nominated candidates for the election of four Directors to its Central Board. The election is scheduled to take place during the General Meeting of Shareholders on May 15, 2026. The candidates possess diverse expertise in areas such as Chartered Accountancy, Actuarial science, IT strategy, and risk management. This process is being conducted under Section 19(c) of the State Bank of India Act, 1955, and complies with the latest RBI governance directions.
முக்கிய அம்சங்கள்
Eight candidates nominated for the election of four Directors to the Central Board.Election scheduled for May 15, 2026, at 03:00 PM via Video Conferencing.Candidate pool includes 4 Chartered Accountants and experts with over 30-40 years of experience in banking and insurance.Nominations are compliant with RBI (Commercial Banks - Governance) Directions, 2025.Candidates include a mix of existing directors like Dharmendra Singh Shekhawat and new industry veterans.
👀 கவனிக்க வேண்டியவை
Shareholders should review the professional backgrounds of the eight candidates to participate effectively in the voting process on May 15. The selection of directors with strong compliance and digital transformation backgrounds is a positive sign for the bank's long-term governance.
Nath Bio-Genes FY26 Revenue Grows 19% to ₹4,316 Mn; Margins Contract to 12%
Nath Bio-Genes reported a strong 19% YoY revenue growth for FY26, reaching ₹4,316 million, driven by robust performance in Cotton (+28% value) and Maize (+78% value). However, profitability was under pressure as EBITDA remained flat at ₹525 million and Gross Margins compressed from 63% to 56%. A key highlight is the international expansion milestone, with Uzbekistan contributing ₹150 million to the top line for the first time. Despite the revenue jump, PAT (adjusted) declined by 8% YoY to ₹384 million.
முக்கிய அம்சங்கள்
Revenue increased by 19% YoY to ₹4,316 Mn, while EBITDA remained stagnant at ₹525 Mn.Cotton Bt volumes grew 22.35% with average realization rising to ₹293/kg.Gross Margin saw a significant contraction to 56% in FY26 from 63% in the previous year.International operations in Uzbekistan achieved a landmark ₹150 Mn revenue contribution.Net Debt increased significantly to ₹510 Mn from ₹235 Mn in FY25.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's ability to recover margins and manage rising debt levels despite healthy top-line growth. The successful scale-up in Uzbekistan and growth in the Maize segment are positive long-term indicators to watch.
Nath Bio-Genes FY26 Revenue Up 19% to ₹431.6 Cr; Recommends ₹2 Dividend
Nath Bio-Genes (India) Limited reported a 19.1% growth in annual revenue for FY26, reaching ₹431.60 crore compared to ₹362.31 crore in FY25. Annual net profit saw a modest increase of 5.4% to ₹44.43 crore, despite a weaker fourth quarter where profit dipped to ₹3.79 crore. The Board has recommended a dividend of ₹2 per share (20% of face value). A significant management update includes the more than doubling of the Managing Director's remuneration to ₹1.44 crore per annum.
முக்கிய அம்சங்கள்
Annual Revenue from operations grew 19.1% YoY to ₹431.60 crore from ₹362.31 crore.Full-year Net Profit increased to ₹44.43 crore compared to ₹42.14 crore in the previous fiscal.Recommended a final dividend of ₹2.00 per equity share (20%) for FY 2025-26.Managing Director's annual remuneration increased by 118% from ₹66 lakhs to ₹1.44 crore.Inventory levels rose significantly to ₹444.60 crore from ₹330.71 crore YoY, indicating aggressive positioning for the next season.
👀 கவனிக்க வேண்டியவை
Investors should view the steady annual top-line growth and dividend payout positively, though the sharp hike in executive pay and rising inventory levels warrant close monitoring. The stock remains a play on the Indian agricultural cycle and seed demand.
SBI Card Q4 FY26 PAT Rises 14% to ₹609 Cr; Asset Quality Improves as GNPA Drops to 2.41%
SBI Cards reported a steady Q4 FY26 with PAT growing 14% YoY to ₹609 crores, driven by a 31% surge in total spends reaching ₹1.15 trillion. Asset quality showed significant improvement as GNPA fell to 2.41% and credit costs moderated by 55 bps sequentially to 7.7%. Net Interest Margins (NIM) remained healthy at 11.1%, supported by a lower cost of funds at 6.4%. The company maintained its market position with an 18.6% share in cards-in-force and declared an interim dividend of ₹2.50 per share.
முக்கிய அம்சங்கள்
Full-year FY26 PAT reached ₹2,167 crores, marking a 13% YoY growth with total revenue at ₹20,708 crores.Asset quality improved significantly with GNPA reducing by 46 bps QoQ to 2.41% and Stage 2 assets falling to ₹2,090 crores.Total spends for Q4 grew 31% YoY to ₹1.15 trillion, while retail spends for FY26 hit a record ₹3.54 trillion.Net Interest Margin (NIM) for FY26 improved by 31 bps YoY to 11.2%, aided by a 71 bps reduction in the annual cost of funds.New account additions stood at 9.17 lakhs for Q4, with a sourcing mix of 54% from the open market and 46% from banca channels.
👀 கவனிக்க வேண்டியவை
Investors should take confidence in the improving asset quality and moderating credit costs, which have been primary concerns for the stock. The company's ability to maintain double-digit NIMs despite a calibrated acquisition strategy makes it a strong hold for long-term credit growth exposure.
SBI Schedules Analyst Meet on May 8, 2026, Following Q4FY26 Results
State Bank of India (SBIN) has announced an interaction with analysts and institutional investors scheduled for May 8, 2026, at 5:15 PM. This meeting will take place immediately following the declaration of the bank's Q4FY26 financial results. The event will be conducted in a hybrid format, featuring an in-person meeting at State Bank Bhavan, Mumbai, alongside a live webcast. This is a critical event for investors to understand the bank's performance trajectory and management's outlook for the next fiscal year.
முக்கிய அம்சங்கள்
Analyst and Institutional Investor meet scheduled for May 8, 2026, at 5:15 PM IST.The meeting is timed to follow the declaration of Q4FY26 financial results.Hybrid attendance options provided via in-person meet in Mumbai and a live webcast link.Management presentation will be made available on stock exchanges and the bank's website post-results.Discussion will be limited to information already available in the public domain.
👀 கவனிக்க வேண்டியவை
Investors should monitor the Q4 results and the subsequent management commentary for insights into credit growth, NIM trends, and asset quality guidance. The webcast link provides a transparent way for retail investors to hear management's strategic priorities firsthand.
Bigbloc Construction Receives Regulatory Approval for Merger of Subsidiary Companies
Bigbloc Construction Limited has received the final order from the Regional Director (NWR) for the merger of its subsidiary, Starbigbloc Building Material Limited, into its wholly-owned subsidiary, Bigbloc Building Elements Private Limited. The merger is effective from the appointed date of April 1, 2025, following approval under Section 233 of the Companies Act, 2013. This internal restructuring is designed to streamline the company's corporate structure and consolidate its building material operations. The official order was pronounced on April 28, 2026, and received by the company on May 2, 2026.
முக்கிய அம்சங்கள்
Merger of Starbigbloc Building Material Ltd into Bigbloc Building Elements Pvt Ltd approved by Regional Director.The appointed date for the merger is retrospective, set as April 1, 2025.Restructuring conducted under the fast-track merger provisions of Section 233 of the Companies Act, 2013.Consolidation aims to achieve operational synergies and reduce administrative overheads across subsidiaries.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive move towards corporate simplification and operational efficiency. No immediate action is required as this is an internal consolidation of existing business units.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
